Skip to main content

Table 1 Recurrent sCNAs in peripheral blood primary CLL samples

From: Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics

sCNA Frequency in CLL (%) Likely target Frequency in MBL (%) More common IGHV status Prognostic significance
del(13q14) 57 to 61 [26, 27] miR-15a/16, encoded in an intron of DLEU2 [8]. Its deletion leads to the release of BCL2 from microRNA-mediated down-regulation [28] 48 [112] None Good [9]
del(11q22.3) 6 to 27 [26, 27] ATM, BIRC3 Rare Unmutated Poor [9]
Trisomy 12 11 to 12 [26, 27] Unknown [7] 20 [112] None None [9]
del(17p) 6 to 8 [26, 27] TP53 Rare Unmutated Poor [9]
amp(2p) 7 [27] XPO1, BCL11A Unknown Unmutated None [27]
amp(8q24.21) 5 [26, 27] MYC Unknown Unmutated Poor [26, 27]
del(15q15.1) 4 [27] MGA Unknown Unknown None [27]
del(10)(q24) 2 [27] NFKB2 Unknown Unknown Unknown
del(18p) 3 [27] Unknown Unknown Unmutated [27] Unknown
del(6q) 7 [27] Unknown Unknown Unknown Unknown
amp(3q26.32) 6 [26] PIK3CA Unknown Unknown Poor [26]
del(8p) 5 [23, 26] Unknown Unknown Unknown Poor [26]
  1. amp, amplification; sCNA, somatic copy number alterations; MBL, monoclonal B-cell lymphocytosis.